Tango Therapeutics, Inc.

TNGXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1819133

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$36.5M	$24.9M	$24.9M	$37.0M	$7.7M
Research and Development Expense	$115.2M	$105.9M	$105.9M	$77.6M	$50.0M
Operating Expenses	$150.7M	$135.9M	$135.9M	$95.2M	$59.9M
Operating Income (Loss)	-$114.2M	-$111.1M	-$111.1M	-$58.2M	-$52.2M
Nonoperating Income (Expense)	$12.6M	$2.9M	$2.9M	$247.0K	$228.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$101.6M	-$108.1M	-$108.1M	-$57.9M	-$52.0M
Income Tax Expense (Benefit)	$134.0K	$54.0K	$54.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$316.5M	$402.6M	$436.5M	$500.2M	$207.3M
Assets, Current	$266.3M	$346.5M	$375.3M	$492.3M	$193.6M
Cash and Cash Equivalents, at Carrying Value	$66.4M	$60.0M	$60.0M	$142.7M	$28.4M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$2.0M	$2.0M	$2.0M
Liabilities	$117.0M	$149.5M	$187.0M	$155.4M	$168.7M
Liabilities, Current	$38.2M	$45.9M	$55.5M	$40.7M	$40.9M
Accounts Payable, Current	$1.6M	$2.8M	$4.5M	$3.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$118.0M	-$109.1M	-$109.1M	-$59.5M	$70.1M
Net Cash Provided by (Used in) Investing Activities	$41.4M	$26.4M	$26.4M	-$183.4M	-$145.5M
Net Cash Provided by (Used in) Financing Activities	$82.4M	$1.6M	$1.6M	$357.3M	$80.9M
Payments to Acquire Property, Plant, and Equipment	$1.5M	$7.7M	$7.7M	$1.8M	$1.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)